As aging biology moves from theory to translation, the field faces a unique set of challenges before its promise can be realised in humans: regulatory ambiguity, lack of validated biomarkers, high-risk investment landscapes, complex clinical trial design, and scientific hype outpacing clinical data.

This forum brings together biotech leaders, pharma, investors, and translational researchers to overcome these barriers and accelerate the path from discovery to real-world intervention.